SBC Medical Group Holdings Inc SBC
We were originally incorporated in Delaware on March 11, 2022 under the name "Pono Capital Two, Inc.," referred to herein as "Pono," as a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
On August 9, 2022, Pono consummated its IPO of 11,500,000 units (the "Units" and, with respect to the Class A common stock included in the Units being offered, the "Public Shares" and with respect to the warrants included in the Units, the "Public Warrants") (the "Pono IPO").
Simultaneously with the consummation of the closing of the Pono IPO, Pono consummated the private placement of an aggregate of 634,375 units (the "Placement Units") at a price of $10.00 per Placement Unit in a private placement to the Sponsor (the "Private Placement").
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $173.6M | $205.4M | $193.5M | — |
| Cost of revenue | $46.3M | $49.4M | $56.2M | — |
| Gross profit | $127.3M | $156.1M | $137.3M | — |
| SG&A | $59.8M | $57.7M | $66.2M | — |
| Total operating expenses | $59.8M | $85.7M | $66.6M | — |
| Operating income | $67.5M | $70.3M | $70.7M | — |
| Interest expense | $148.2K | $28.3K | $45.3K | — |
| Pre-tax income | $82.1M | $73.5M | $73.6M | — |
| Income tax | $31.0M | $26.8M | $35.0M | — |
| Net income | $51.0M | $46.6M | $39.4M | — |
| EPS, basic | 0.50 | 0.48 | 0.42 | — |
| EPS, diluted | 0.50 | 0.48 | 0.42 | — |
| Shares, diluted (wtd. avg.) | 103.0M | 96.6M | 94.2M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Cash and equivalents | $163.8M | $125.0M | $103.0M | $485.6K |
| Short-term investments | $319.2K | $0 | — | — |
| Inventory | $2.8M | $1.5M | $3.1M | — |
| Total current assets | $231.2M | $184.5M | $165.9M | $722.2K |
| Property, plant and equipment | $7.5M | $8.8M | $13.6M | — |
| Goodwill | $15.4M | $4.6M | $3.6M | — |
| Other intangibles | $47.7M | $1.6M | $19.7M | — |
| Total assets | $380.4M | $266.1M | $258.8M | $119.9M |
| Accounts payable | — | — | $43.9K | $79.4K |
| Short-term debt | $228.2K | $262.1K | $329.2K | — |
| Total current liabilities | $61.1M | $61.2M | $92.5M | $566.0K |
| Long-term debt | $42.8M | $6.6M | — | — |
| Total liabilities | $117.1M | $71.1M | $115.0M | $4.6M |
| Retained earnings | $240.4M | $189.5M | $142.8M | -$3.4M |
| Total equity | $248.3M | $195.1M | $143.8M | $107.9M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Operating cash flow | $24.7M | $20.6M | $50.7M | — |
| Depreciation and amortisation | $2.7M | $3.8M | $12.2M | — |
| Stock-based compensation | $0 | $13.0M | — | — |
| Capital expenditure | $1.4M | $2.6M | $8.5M | — |
| Investing cash flow | -$21.0M | -$10.1M | $1.8M | — |
| Financing cash flow | $38.3M | $23.0M | $6.1M | — |
| Buybacks | $5.0M | $0 | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-020748.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | — | $193.5M | $205.4M | $173.6M |
| Gross profit | — | $137.3M | $156.1M | $127.3M |
| Net income | — | $39.4M | $46.6M | $51.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
- Shareholder rights changed The terms attaching to the shares themselves have changed. Item 3.03
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8011
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| HIMS | Hims & Hers Health, Inc. | $6.42B | 54.3x | 59.0% |
| TDOC | Teladoc Health, Inc. | $1.15B | — | -1.5% |
| STLN | Starling Oncology, Inc. | $683.9M | — | 27.8% |
| LFMD | LifeMD, Inc. | $102.7M | 8.5x | 25.3% |
| AIRS | Airsculpt Technologies, Inc. | $86.5M | — | -15.8% |
| CCM | Concord Medical Services Holdings Ltd | — | — | 26.6% |
| BMGL | Basel Medical Group Ltd | — | — | — |